Evidence map›Paper›PMID 39448881›Full record

ArticleNature biotechnology2025

Gold-siRNA supraclusters enhance the anti-tumor immune response of stereotactic ablative radiotherapy at primary and metastatic tumors.

Yuyan Jiang, Hongbin Cao, Huaping Deng, Li Guan, Jimpi Langthasa, Deana Rae Crystal Colburg, Stavros Melemenidis, Renee M Cotton, John Aleman, Xiao-Jing Wang and 5 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07562841 (Safety and Tolerability of Au-TMP Nanoparticles in Combination With Radiotherapy for Patients With Advanced Melanoma Receiving Anti-PD-1 Therapy), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07562841 phase1recruitingnot on this mapstarted 2026, after this paper: background citation

Safety and Tolerability of Au-TMP Nanoparticles in Combination With Radiotherapy for Patients With Advanced Melanoma Receiving Anti-PD-1 Therapy

TypeinterventionalSponsorWest China HospitalRan2026 to 2029Enrolled6ConditionsAdvanced MelanomaArmsAu-TMP, Fractionated Radiotherapy (RT), Toripalimab
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yuyan JiangDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-8280-6846
Hongbin CaoDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Huaping DengDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Li GuanDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Jimpi LangthasaDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-7675-2458
Deana Rae Crystal ColburgDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-8287-9455
Stavros MelemenidisDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Renee M CottonDepartment of Comparative Medicine, Stanford University, Stanford, CA, USA.
John AlemanDepartment of Pathology, University of Colorado, Anschutz Medical Campus, Aurora, CO, USA.ORCID http://orcid.org/0000-0002-1691-6262
Xiao-Jing WangDepartment of Pathology and Laboratory Medicine, School of Medicine, University of California, Davis, Sacramento, CA, USA.ORCID http://orcid.org/0000-0001-8695-7361
Edward E GravesDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Anusha KalbasiDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA.
Kanyi PuSchool of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, Singapore, Singapore.ORCID http://orcid.org/0000-0002-8064-6009
Jianghong RaoDepartment of Chemistry, Stanford University, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-5143-9529
Quynh-Thu LeDepartment of Radiation Oncology, Stanford University, Stanford, CA, USA. qle@stanford.edu.ORCID http://orcid.org/0000-0002-3682-1439

Funding

Translational Biology CoreP01CA257907 · NCI · STANFORD UNIVERSITY · PI Quynh-Thu Xuan Le · 2022 to 2026
$12.0M
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.P50CA261605 · NCI · UNIVERSITY OF COLORADO DENVER · PI LUCIA, M. SCOTT · 2021 to 2025
$10.1M
Systems Biology of Tumor-Immune-Stromal Interactions in Metastatic ProgressionU54CA274511 · NCI · STANFORD UNIVERSITY · PI JOSEPH B SHRAGER · 2023 to 2026
$9.5M
The role of Galectin-1 in shaping the immune suppressive landscape in head and neck cancerR01DE029672 · NIDCR · STANFORD UNIVERSITY · PI LE, QUYNH-THU XUAN · 2021 to 2025
$2.9M
BLRD VA IK6 BX006039NCI NIH HHS P01 CA257907NCI NIH HHS P50 CA261605NCI NIH HHS U54 CA274511NIDCR NIH HHS R01 DE029672U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P01CA257907U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research (NIDCR) R01DE029672
6 · The paper itself

Abstract

Strategies to enhance the anti-tumor immune response of stereotactic ablative radiotherapy (SABR) at primary tumors and abscopal sites are under intensive investigation. Here we report a metabolizable binary supracluster (BSC

Indexed as

GoldHead and Neck NeoplasmsNeoplasmsRadiosurgeryRNA, Small InterferingAnimalsCell Line, TumorFemaleGalectin 1HumansMetal NanoparticlesMiceNeoplasm MetastasisRadiation-Sensitizing AgentsGalectin 1GoldRadiation-Sensitizing AgentsRNA, Small Interfering

Identifiers

PMID39448881
PMCPMC12018592

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.